Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Mar;27(2):101-107.
doi: 10.1111/ajad.12660. Epub 2018 Feb 19.

Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder

Christina A Brezing  1   2 , C Jean Choi  3 , Martina Pavlicova  4 , Daniel Brooks  1 , Amy L Mahony  1 , John J Mariani  1   2 , Frances R Levin  1   2
Affiliations
Randomized Controlled Trial

Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder

Christina A Brezing et al. Am J Addict. 2018 Mar.

Abstract

Background and objective: Many patients with cannabis use disorder (CUD) do not achieve or do not have abstinence as a goal of treatment, rather they reduce their use. Assessing outcome measures as they relate to functioning and reductions in cannabis use is an important area of study. Quality of life (QoL) shows promise as one such measure. Past studies have demonstrated gender differences in QoL and CUD. We aim to assess (1) the relationship between cannabis use and QoL and (2) gender effects in an outpatient medication treatment study for CUD.

Methods: Data from an 11-weeks, double-blind, placebo-controlled trial of lofexidine and dronabinol for CUD (n = 62) was analyzed. Pearson's correlations between baseline QoL as measured with the Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (QLES-Q-SF) and cannabis use assessed with modified timeline follow-back (TLFB) were examined. Multiple linear regression models of cannabis use on end of study QLES-Q-SF were analyzed, while adjusting for baseline QLES-Q-SF, study arm, and gender. Moderation effects with gender were also tested.

Results: No significant association between baseline cannabis use and QoL was found. End of study abstinence (F1,47 = 8.34, p = .006) and reduced proportion of using days (F1,47 = 9.48, p = .004) were each significantly associated with end of study QoL. Reduction in grams (F1,27 = 0.25, p = .62) was not associated with QoL at end of study. Gender was not a significant moderator.

Discussion and conclusions: Abstinence and lower frequency of use are associated with higher QoL, regardless of gender.

Scientific significance: This is the first time QoL has been demonstrated to change over the course of CUD medication treatment. QoL is an important outcome in CUD treatment.

Trial registration: NCT01020019. (Am J Addict 2018;27:101-107).

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest

Drs. Brezing, Pavlicova, Mariani, Ms. Choi, Mr. Brooks, and Ms. Mahony report no competing interests and no financial relationships with commercial interests. Dr. Levin received medication from the US WorldMed for this trial and served as a consultant to GW Pharmaceuticals and Eli Lily. The authors alone are responsible for the content and writing of this paper.

Figures

FIGURE 1
FIGURE 1
Plot of model adjusted QLES-Q-SF at week 12 and last 2 weeks abstinence (N = 52).
FIGURE 2
FIGURE 2
Plot of model adjusted QLES-Q-SF at week 12 and proportion of using days during the last 2 weeks (N = 52).
FIGURE 3
FIGURE 3
Plot of model adjusted QLES-Q-SF at week 12 and reduction in grams of cannabis used from average weekly use at baseline to average weekly use during weeks 9–12 (N = 32).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: Current science and future outlook. Pharmacotherapy. 2016;36:511–535. - PMC - PubMed
    1. Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep. 2014;1:137–143. - PMC - PubMed
    1. Levin FR, Mariani JJ, Pavlicova M, et al. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2016;159:53–60. - PMC - PubMed
    1. Hall W, Kozlowski LT. The diverging trajectories of cannabis and tobacco policies in the United States: Reasons and possible implications. Addiction. 2017:22. - PubMed
    1. Gonzalez-Saiz F, Rojas OL, Castillo II. Measuring the impact of psychoactive substance on health-related quality of life: An update. Curr Drug Abuse Rev. 2009;2:5–10. - PubMed

Publication types

MeSH terms

Associated data